aclacinomycin has been researched along with Leukemia, Myeloid, Acute in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (50.00) | 18.7374 |
| 1990's | 1 (5.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (30.00) | 24.3611 |
| 2020's | 3 (15.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bo, J; Dou, L; Gao, C; Gao, X; Li, H; Liu, D; Lu, N; Wang, L; Wei, Y; Wu, Y; Zhang, R; Zhu, C | 1 |
| Chang, J; Jin, J; Shen, YJ; Wang, HF; Ye, XN; Zhang, Y; Zhu, HH; Zhu, L | 1 |
| Bian, Y; Huang, C; Ma, S; Ma, W; Miao, L; Miao, M; Xia, F; Yu, D | 1 |
| Bai, X; Guo, K; Guo, Z; He, H; He, X; Qiu, D; Wang, J; Weng, G; Xu, X; Ye, Y; Yi, W; Zhang, M; Zhou, R | 1 |
| Cao, XM; Chen, YX; Gu, LF; He, AL; Lei, B; Liu, J; Ma, XR; Wang, FX; Wang, J; Wang, JL; Xu, Y; Yang, Y; Zhang, PY; Zhang, WG; Zhao, WH | 1 |
| Cao, YB; DA, WM; Li, SW; Li, XH; Liu, B; Liu, ZY; Wu, XX; Wu, YM; Xu, LX; Yan, B; Yang, XL | 1 |
| Fan, C; Huang, J; Jin, J; Mai, W; Mao, L; Meng, H; Qian, W; Suo, S; Tong, H; Yu, W | 1 |
| Chang, CK; He, Q; Li, X; Song, LX; Wu, LY; Xu, L; Zhang, QX; Zhang, Y | 1 |
| Chen, L; Mi, R; Wei, X; Yin, Q | 1 |
| Yamada, K | 1 |
| Mitrou, PS | 1 |
| Kobayashi, M; Tahara, T | 1 |
| de Vassal, F; Delgado, M; Dorval, T; Gastiaburu, J; Goldschmidt, E; Hulhoven, R; Machover, D; Misset, JL; Ribaud, P; Tapiero, H | 1 |
| Abe, Y; Hatanaka, T; Ito, T; Kamiya, O; Nagata, K; Ohara, K; Ono, Y; Saito, M | 1 |
| Han, J; Jia, TZ; Liu, HY; Lu, Y; Yang, S; Zhong, GP | 1 |
| Mochizuki, T; Okazaki, T; Sawada, H; Tashima, M; Uchino, H | 1 |
| Ehninger, G; Freund, M; Heil, G; Hoelzer, D; Kurrle, E; Link, H; Mitrou, PS | 1 |
| Fink, FM; Gadner, H; Grümayer, ER; Kardos, G; Revesz, T; Schuler, D | 1 |
| Lutz, D | 1 |
| Marie, JP; Thevenin, D; Zittoun, R | 1 |
3 trial(s) available for aclacinomycin and Leukemia, Myeloid, Acute
| Article | Year |
|---|---|
A phase II study of chidamide, cytarabine, aclarubicin, granulocyte colony-stimulating factor, and donor lymphocyte infusion for relapsed acute myeloid leukemia and myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation.
Topics: Aclarubicin; Adult; Cytarabine; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Lymphocytes; Myelodysplastic Syndromes; Recurrence | 2023 |
Clinical outcome of treatment with a combined regimen of decitabine and aclacinomycin/cytarabine for patients with refractory acute myeloid leukemia.
Topics: Aclarubicin; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Survival; Cyclin-Dependent Kinase Inhibitor p15; Cytarabine; Decitabine; DNA Methylation; DNA Modification Methylases; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Leukemia, Myeloid, Acute; Leukocytes, Mononuclear; Male; Middle Aged; Recurrence; Remission Induction; Survival Analysis; Tumor Cells, Cultured; Young Adult | 2012 |
[New agents in the treatment of leukemia and lymphoma].
Topics: Aclarubicin; Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Clinical Trials as Topic; Cytarabine; Doxorubicin; Drug Evaluation; Humans; Infusions, Parenteral; Leukemia, Myeloid, Acute; Lymphoma; Middle Aged; Naphthacenes | 1983 |
17 other study(ies) available for aclacinomycin and Leukemia, Myeloid, Acute
| Article | Year |
|---|---|
CAG (cytarabine, aclarubicin and granulocyte colony-stimulating factor) regimen for core binding factor acute myeloid leukaemia with measurable residual disease.
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Core Binding Factors; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Neutropenia; Retrospective Studies; Treatment Outcome | 2023 |
A retrospective study of the correlation of in vitro chemosensitivity using ATP-TCA with patient clinical outcomes in acute myeloid leukemia.
Topics: Aclarubicin; Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Decitabine; Female; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Remission Induction; Retrospective Studies; Young Adult | 2020 |
Low-dose arsenic trioxide combined with aclacinomycin A synergistically enhances the cytotoxic effect on human acute myelogenous leukemia cell lines by induction of apoptosis.
Topics: Aclarubicin; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Gene Expression; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Oxides | 2015 |
[Cohort Study on GHA and New Combined Priming Chemotherapeutic Regimens in Treatment of Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome].
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; B7-1 Antigen; Cohort Studies; Cytarabine; Doxorubicin; Granulocyte Colony-Stimulating Factor; Granulocytes; Harringtonines; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Recurrence; Thrombocytopenia | 2015 |
[Clinical Efficacy of Decitabine Combined with CAG Regimen for Myelodysplastic Syndrome-RAEB and Refractory Acute Myeloid Leukemia].
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Granulocyte Colony-Stimulating Factor; Humans; Karyotype; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Pancytopenia; Recurrence; Remission Induction; Retrospective Studies; Survival Rate; Treatment Outcome | 2015 |
[Efficacy of HAA regimen in the treatment of 64 patients with refractory/relapsed acute myeloid leukemia].
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Harringtonines; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Rate | 2016 |
CHAG priming regimen containing of cytarabine, aclacinomycin homoharringtonine and G-CSF for relapsed refractory acute myelogenous leukemia: a modified combination chemotherapeutic combination.
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Granulocyte Colony-Stimulating Factor; Harringtonines; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Treatment Outcome | 2013 |
[Therapeutic results with aclacinomycin A in recurring acute leukemias].
Topics: Aclarubicin; Adolescent; Adult; Antibiotics, Antineoplastic; Female; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Middle Aged; Naphthacenes; Recurrence | 1983 |
[Adriamycin-aclacinomycin therapy (AA therapy) for acute leukemia unresponsive to BH-AC-DMP therapy].
Topics: Aclarubicin; Adolescent; Adult; Aged; Cytarabine; Daunorubicin; Doxorubicin; Drug Resistance; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Naphthacenes; Prednisolone | 1983 |
Phase I-II study of aclacinomycin for a treatment of acute myeloid leukemia.
Topics: Aclarubicin; Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Child; Child, Preschool; Drug Evaluation; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Naphthacenes | 1984 |
[Short-term intensive consolidation chemotherapy in the treatment of acute nonlymphocytic leukemia].
Topics: Aclarubicin; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Prognosis; Survival Rate; Vinblastine; Vincristine | 1994 |
[Differentiation of human promyelocytic leukemic cells (HL-60) induced by aclacinomycin-B].
Topics: Aclarubicin; Antibiotics, Antineoplastic; Cell Differentiation; Cell Line; Humans; Leukemia, Myeloid, Acute; Naphthacenes | 1986 |
Magnesium deprivation inhibits the expression of differentiation-related phenotypes in human promyelocytic leukemia HL-60 cells.
Topics: Aclarubicin; Amanitins; Bucladesine; Calcitriol; Cell Differentiation; Cell Division; Cell Line; Cycloheximide; Dimethyl Sulfoxide; Drug Interactions; Humans; Leucine; Leukemia, Myeloid, Acute; Magnesium Deficiency; Naphthacenes; Oncogenes; Peptide Chain Elongation, Translational; Phenotype; RNA, Messenger; Tetradecanoylphorbol Acetate; Tretinoin | 1987 |
Age adapted induction and intensified consolidation therapy in acute myelogenous leukemia.
Topics: Aclarubicin; Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Naphthacenes; Prognosis | 1986 |
Aclacinomycin-A in the induction treatment of childhood AML.
Topics: Aclarubicin; Adolescent; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Daunorubicin; Etoposide; Female; Follow-Up Studies; Humans; Infant; Infusions, Parenteral; Leukemia, Myeloid, Acute; Male; Naphthacenes; Thioguanine | 1986 |
[Various induction therapies in older patients with acute myeloid leukemias].
Topics: Aclarubicin; Adolescent; Adult; Aged; Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Danazol; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Leukapheresis; Leukemia, Myeloid, Acute; Male; Middle Aged; Naphthacenes; Tamoxifen | 1985 |
In vitro sensitivity of leukemic clonogenic cells to four anthracyclines (adriamycin, daunorubicin, rubidazone and aclacinomycin) in human acute myeloid leukemia.
Topics: Aclarubicin; Aged; Bone Marrow; Cells, Cultured; Child; Daunorubicin; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance; Humans; Leukemia, Myeloid, Acute; Middle Aged; Naphthacenes | 1985 |